StreetInsider.com News Articles

NorthStrive files two patents for muscle-loss drugs in spaceflight

Fri, 21 Aug 2026 09:30:43 -0400

NorthStrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), has filed two U.S. patent applications covering the use of its preclinical drug candidates EL-22 and EL-32 to preserve lean muscle mass in humans exposed to microgravity during spaceflight.

The applications were assigned U.S. Patent Application Nos. 19/774,556 for EL-22 and 19/774,575 for EL-32. EL-22 targets myostatin, while EL-32 targets both myostatin and activin A, proteins that suppress skeletal muscle growth.

The filings extend the same biological approach NorthStrive is pursuing for muscle preservation in patients undergoing GLP-1 receptor agonist and other obesity-related weight loss treatment to a separate patient population:

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

Fri, 21 Aug 2026 09:30:00 -0400

New Filings Extend EL-22 and EL-32 into Spaceflight-Associated Muscle Atrophy, Broadening NorthStrive’s Myostatin and Activin A Intellectual Property Portfolio Across Human Weight-Loss, Space Health and Animal Health Applications

The filings are intended to position EL-22 and EL-32 as potential muscle-preservation platforms not only for large terrestrial markets, but also for the emerging medical requirements associated with sustained human presence in space

NEWPORT BEACH, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the filing

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

Fri, 21 Aug 2026 09:30:00 -0400

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

Fri, 21 Aug 2026 09:30:00 -0400

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

Fri, 21 Aug 2026 09:30:00 -0400

PMGC Holdings announces 1-for-10 reverse stock split for Aug. 21

Wed, 19 Aug 2026 11:45:07 -0400

PMGC Holdings Inc. (NASDAQ: ELAB) announced a 1-for-10 reverse stock split of its issued and outstanding common stock, effective at 12:00 a.m. Eastern time on August 21, 2026, according to a press release.

Every 10 shares of common stock will be consolidated into one share, with no action required from shareholders. The company anticipates approximately 809,584 shares of common stock will be outstanding immediately following the split, down from approximately 8,095,835 shares outstanding immediately prior to the split.

The company's trading symbol on the Nasdaq will remain "ELAB," but the common stock will be assigned a new CUSIP number: 73017P 607.

Shareholders entitled

PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

Wed, 19 Aug 2026 11:45:00 -0400

NEWPORT BEACH, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-10 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”), effective at 12:00 am, Eastern time, on August 21, 2026.

Key Details of the Reverse Stock Split:

Conversion Ratio: Every 10 shares of issued and outstanding Common Stock will be consolidated into one share of Common Stock, and every 10 shares of authorized Common Stock will be

PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

Wed, 19 Aug 2026 11:45:00 -0400

Key Details of the Reverse Stock Split:

Conversion Ratio: Every 10 shares of issued and outstanding Common Stock will be consolidated into one share of Common Stock, and every 10 shares of authorized Common Stock will be

Form 10-Q PMGC Holdings Inc. For: Jun 30

Fri, 14 Aug 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260814/26926005.html

Form 10-Q PMGC Holdings Inc. For: Jun 30

Fri, 14 Aug 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260814/26926005.html

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-over-Year, as Quarterly Revenue Nearly Doubles

Fri, 14 Aug 2026 09:31:00 -0400

NEWPORT BEACH, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("PMGC" or the "Company"), a diversified holding company, has filed its Quarterly Report on Form 10-Q (the "Quarterly Report") for the three and six months ended June 30, 2026, with the U.S. Securities and Exchange Commission ("SEC").

The Quarterly Report is available on the SEC's website at www.sec.gov under the Company's filings.

Q2 2026 was a quarter of meaningful revenue and balance sheet growth, driven by the Company's operating platform and continued M&A execution, including the closing of the A&B Aerospace, Inc.

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-over-Year, as Quarterly Revenue Nearly Doubles

Fri, 14 Aug 2026 09:31:00 -0400

The Quarterly Report is available on the SEC's website at www.sec.gov under the Company's filings.

Q2 2026 was a quarter of meaningful revenue and balance sheet growth, driven by the Company's operating platform and continued M&A execution, including the closing of the A&B Aerospace, Inc.

PMGC Holdings says it meets Nasdaq's new $5M market value rule

Wed, 29 Jul 2026 15:55:47 -0400

PMGC Holdings Inc. (Nasdaq: ELAB) stated that it is in compliance with Nasdaq's newly approved Market Value of Listed Securities requirement, which took effect immediately upon approval by the Securities and Exchange Commission.

Under the new rule, companies listed on Nasdaq markets must maintain a minimum market value of listed securities. A company whose market value remains below the minimum for 30 consecutive business days may face trading suspension and delisting proceedings without a cure period. PMGC said its market value of listed securities exceeds the new $5 million minimum based on its share count and market price as of July

PMGC Holdings Confirms Compliance with Nasdaq’s New $5 Million Market Value of Listed Securities Requirement